Hematopoietic stem cell transplantation (HSCT) treats disorders affecting patients of all ages. We studied the rate-corrected cardiac QT interval (QTc) in 995 consecutive children and adults undergoing HSCT at the University of Minnesota. We sought to (1) describe QTc before and after HSCT; (2) describe the change in QTc after HSCT; (3) identify factors affecting QTc and its change; and (4) scrutinize an 'at risk' sub-cohort with a long QTc before HSCT. Pre HSCT: 952 (96%) patients had an evaluable electrocardiography (ECG); median QTc was 426 ms and depended upon disease necessitating transplant. Post HSCT: 506 (51%) patients had an evaluable ECG; median QTc was 441 ms. Intrapatient QTc change: 490 (49%) evaluable patients showed median QTc change (pre to post HSCT) of +16 ms (P o0.0001). At risk group: 68 patients were 'at risk' (long pre-HSCT QTc). In some, 'at-risk' status trended toward predictive of post-transplant nonrelapse mortality. QTc interval prolongation is evident in a large, diverse cohort undergoing HSCT at our institution. Prospective studies of this patient population may be warranted, particularly for 'at-risk' patients who demonstrate significant QTc prolongation both pre and post HSCT.
INTRODUCTION
Hematopoietic stem cell transplantation (HSCT) is an increasingly applied therapy for patients with various life-threatening disorders. Initially pioneered in inherited immunodeficiencies, HSCT has demonstrated therapeutic efficacy for diverse indications including hematolymphoid malignancies, non-malignant hematologic diseases, marrow failure, inherited metabolic disorders and nonhematologic malignancies. [1] [2] [3] [4] [5] [6] Data from the National Marrow Donor Program (NMDP) boasts coordination of over 6000 allogeneic transplants in 2013 alone. 7 In allogeneic HSCT, a therapeutic effect generally follows provision of normal, ordered, donor-derived hematopoiesis after successful engraftment of hematopoietic stem cells. Patients undergo pre-HSCT conditioning (chemotherapy, radiation and/or immune therapy) for the purpose of antineoplastic effect, reduction in the allo-engraftment barrier, or both. In autologous HSCT, 'rescue' of unintended marrow aplasia following myeloablative anti-tumor therapy is the goal. 8 Several factors have contributed to the expanding application of successful HSCT, including access to better antimicrobial therapies, improved understanding of regimen-related toxicities, advanced donor/recipient HLA typing techniques and effective reduced-intensity conditioning strategies. [9] [10] [11] [12] Yet, HSCT carries significant risks for morbidity and mortality from various complications such as vital organ failure from direct chemoradiation toxicity. 13 As such, HSCT candidates frequently undergo rigorous organ function assessment before the initiation of conditioning regimens. Standard cardiac assessments for HSCT recipients include echocardiography (ECHO) and electrocardiography (ECG).
14 Although cardiac function status assessed by ECHO often informs candidacy for HSCT, conditioning intensity to be applied, or both, the presence of clinically 'silent' abnormalities in the candidate's cardiac electrophysiologic signature may have less straightforward implications. The cardiac QT interval (QT) has gained deserved scrutiny among electrophysiologists. The QT (when corrected for ventricular rate, QTc) reflects the duration of the ventricular myocardial depolarization/repolarization cycle. QTc is known to depend upon multiple factors, such as autonomic tone, density and behavior of ion channels which dictate potentials across cardiomyocyte membranes, and medication interactions and interplay with transmembrane channels. 15 Ion flux perturbations (due to intrinsic or extrinsic abnormalities of membrane-bound ion channel number, structure or function) can predispose to QTc prolongation, and therefore pre-arrhythmia expression. 16 Indeed, cause and effect of QT prolongation is well inferred by studies of patients with inherited long QT syndrome (LQTS). 17 However, certain drug exposures as well as abnormal serum electrolyte concentrations are known to alter QTc in those without known familial predisposition, likely via influence upon transmembrane channels, thus affecting ion flux. 18, 19 Ultimately, QTc prolongation is associated with an increased risk of tachy-arrhythmias and sudden death, though absolute values for risk determination are not so clearly established. 20 We aimed to retrospectively study ventricular rate-corrected QTc intervals in a large group of children and adults undergoing HSCT for diverse underlying disease at our institution. Specifically, for this cohort we sought to (1) describe the QTc in both pre-and post-HSCT settings; (2) describe the change in QTc after HSCT; (3) identify patient-related and transplant-related characteristics 1 that may predict QTc and its change over time; and (4) further scrutinize an 'at-risk' subpopulation identified by long QTc in the pre-HSCT setting for medication exposure, electrolyte status and nonrelapse mortality following HSCT. To our knowledge, this study of QTc in an HSCT population is the largest of its kind.
MATERIALS AND METHODS

Cohort selection
All children and adults undergoing allogeneic or autologous HSCT at the University of Minnesota over five consecutive years were identified by query of the University of Minnesota Blood and Marrow Transplant Program Database (BMT Database). For any patient undergoing multiple transplants, only the first HSCT was considered.
HSCT-related data
Patient and transplant-related data (demographics, primary diagnosis, HSCT preparative regimen, HSCT date, GvHD prophylaxis, HSCT comorbidity index score (HSCT-CI) and survival status) were obtained from the prospectively maintained BMT Database. Serum electrolyte and medication exposure data for patients of interest ('at-risk' group, defined later) were obtained by retrospective review of medical records at the time point nearest ECG acquisition (within 3 days). Electrolyte values were deemed normal or abnormal (low or high) based on clinical laboratory stated agebased reference ranges. HSCT-CI scores reflected pre-HSCT patient comorbidities, as previously described. 21 
ECG/QTc interval data and analysis
Available ECGs for all cohort members were retrieved from the University of Minnesota MUSE Database. Pre-HSCT screening ECGs were generally performed per BMT Program standard protocol; repeat ECGs were obtained for various clinical indications. All ECGs were cardiologistreviewed at the time of acquisition; none underwent retrospective cardiologist evaluation for the purpose of this analysis. Extracted data included study date, presence or absence of sinus rhythm and recorded QTc. All ECGs exhibiting absence of sinus rhythm were excluded from analysis. ECG time points were categorized as pre or post HSCT with respect to the day of hematopoietic stem cell (HSC) infusion. ECGs obtained on the day of HSC infusion were defined as post-HSCT studies.
For a patient with 41 evaluable pre-HSCT ECG, the mean of that patient's observed pre-HSCT QTc was used for analysis. For patients with 41 evaluable post-HSCT ECG, the mean of that patient's observed post-HSCT QTc was used for analysis. Any ECG obtained 41 year post HSCT was excluded from analysis.
QTc behavior was assessed for patients who had at least one evaluable ECG in both pre-and post-HSCT settings. Change in QTc (ΔQTc) was defined per patient as (mean post-HSCT QTc) − (mean pre-HSCT QTc).
Identification and analysis of an 'at-risk' subgroup A long QTc was defined in both the pre-and post-HSCT settings as a mean QTc ⩾ 460 ms for males (any age) and ⩾ 470 ms for females (any age). An 'at-risk' population was identified within the cohort as those patients satisfying two conditions: (1) demonstrating pre-HSCT long QTc, and (2) without known pre-HSCT HSCT-CI ⩾ 3. This 'at-risk' population was studied for medication exposures and electrolyte status at the time that the longest pre-HSCT QTc was noted (ECG acquisition). This population was also assessed for nonrelapse mortality (NRM), defined as death post HSCT due to any cause other than progression of the underlying disease that necessitated transplantation. Patients demonstrating high HSCT-CI (⩾3) were excluded from the 'at-risk' definition in an attempt to remove possible effects of excessive pre-HSCT comorbidity on QTc and NRM in this analysis.
Statistical considerations
Factors associated with difference in per-patient mean QTc (before and after HSCT) and the per-patient change in mean QTc were analyzed using multivariable linear regression, including age, age squared, gender, diagnosis, graft type and conditioning intensity. GvHD prophylaxis effects were estimated in a separate model that did not include graft type because of the dependency of these two variables. A two-sided paired t-test was used to assess whether per-patient mean QTc changed from pre to post HSCT. The cumulative incidence of nonrelapse mortality was estimated with relapse considered to be a competing risk. 22 Analyses were performed using SAS version 9.2 (SAS Institute, Cary, NC, USA).
RESULTS
Cohort characteristics
Nine hundred and ninety-five consecutive children and adults underwent allogeneic or autologous HSCT over five consecutive years. Patient and HSCT-related characteristics appear in Table 1 .
ECG data and pre-HSCT QTc interval characteristics A total of 2525 ECGs (1139 pre HSCT and 1386 post HSCT) were evaluable for review. An additional 150 ECGs (5.6%) were excluded from analysis due to absence of sinus rhythm.
Nine hundred and fifty-two patients (96%) had an evaluable ECG at a median 22 days before transplantation (interquartile range (IQR), 16-31 days pre HSCT). The cohort's median pre-HSCT QTc was 426 ms, with an IQR of 409-444 ms and range of 330-569 ms ( Figure 1 ). Multivariable regression analysis of patientrelated characteristics (age, sex, disease and planned HSCT type) showed QTc dependence upon age (nadir at age 32 years) and sex (male gender, shorter). QTc also depended upon primary disease. Patients with AML and myeloproliferative disorder (MPD) had significantly longer intervals, while those with metabolic disorders had significantly shorter QTc (Table 2 ). There was a nonlinear relationship between age and QTc; for males, mean QTc was near 430 ms for children under 5 years, decreasing to a minimum of 420 ms at age 30 years and increasing thereafter to 440 ms at age 70 years. Females exhibited a similar pattern though QTc was higher across all ages by 10 ms.
Post-HSCT QTc interval characteristics Five hundred and six (51%) patients had an evaluable ECG within 1 year after transplantation (median time to observation 60 days post HSCT; IQR, 24-130 days post HSCT). The median QTc post HSCT was 441 ms (range, 371-582 ms; IQR, 425-458 ms; Figure 1 ). Multivariable regression analysis of patient-and transplant-related characteristics (age, sex, disease, HSCT type and GvHD prophylaxis) showed QTc dependence upon age and sex (male gender, shorter; nadir at age 30 years). A trend toward QTc prolongation was observed in those receiving cyclosporine and mycophenolate mofetil for GvHD prophylaxis (Table 3) .
Intrapatient QTc interval change after HSCT Four hundred and ninety (49%) patients had at least one evaluable pre-and one evaluable post-HSCT ECG. The median ΔQTc was 16 ms (range, − 63 to 154 ms; IQR, − 2 to 33 ms; Figure 1 ). QTc prolongation for the aggregate cohort was statistically significant (P o0.0001). Multivariable regression analysis of patient-and transplant-related characteristics (age, sex, disease, HSCT type and GvHD prophylaxis) showed less prolongation for patients with AML and MPD. A trend toward less prolongation was also seen in females (Table 4) .
Long QTc interval and the 'at-risk' population An 'at-risk' group of 68 (7%) patients was identified by pre-HSCT characteristics. Inclusion necessitated long pre-HSCT mean QTc (defined for any age as ⩾ 460 ms for males, ⩾ 470 ms for females). To reduce the possible contributing effect of comorbidity on both the QTc as well as post-HSCT NRM, patients with known ; for females, add 9.6 ms.
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pre-HSCT-CI ⩾ 3 (n = 108; 14 with prolonged QTc) were excluded from analysis. 'At-risk' patients did not significantly differ from the remainder of the cohort by age, gender, or HSCT-CI. AML was over represented in this 'at-risk' group (31%) compared with the non 'at-risk' group (17%, P = 0.01), while proportions of other primary diseases for which transplant was imminent were not significantly different.
In the 'at-risk' subset, five patients demonstrated hypokalemia (62 eukalemia, 1 unknown status), six had hypocalcemia (61 eucalcemia, 1 unknown status), and three had hypomagnesemia (17 eumagnesemia, 4 hypermagnesemia, and 44 unkown status) at the time of pre-HSCT ECG assessment. Various exposures at the time of pre-transplant ECG to nonchemotherapeutic drugs associated with QTc prolongation were noted in this group. The most common such drugs (with number of patients exposed) included voriconazole (24); trimethoprim-sulfamethoxazole (19); fluconazole (11); ondansetron (10); levofloxacin (9); citalopram (8); furosemide (5); escitalopram (4); and trazadone (3) . 23 Twenty-two 'at-risk' patients were not on any medication associated with QTc prolongation at the time of baseline ECG, while 19 patients were taking one such agent. Twenty-seven patients were on two or more QTc-prolonging drugs. Eight 'at-risk' patients had both a documented abnormal electrolyte value and were also taking one or more QTc-prolonging medications at baseline ECG. These eight patients demonstrated a mean QTc of 509 ms compared with a mean QTc of 483 ms for others in the 'at-risk' group (P = 0.002).
'At-risk' status alone did not significantly impact NRM (median follow-up of 21 months for survivors). However, trends toward NRM difference were observed when both pre-HSCT 'at-risk' status and presence or absence of post-HSCT long QTc were cofactored in patients with evaluable pre-and post-HSCT ECGs. These differences in NRM were particularly evident in the months immediately following HSCT (See Figure 2) .
DISCUSSION
We report a retrospective analysis of cardiac QTc characteristics and behavior in 995 consecutive adult and pediatric patients undergoing HSCT at our institution over 5 consecutive years. Our data show relatively normal distributions of the cohort's pre-and post-HSCT QTc as noted in the literature. 24, 25 Factors correlating with the pre-HSCT QTc duration included age, gender and in some cases underlying primary disorder necessitating transplant. Factors correlating with post-HSCT QTc also included age and gender, with a trend toward correlation with GvHD prophylaxis treatment. Statistically significant, though modest, QTc prolongation was seen from the pre to post HSCT period for the aggregate cohort. An 'at-risk' population (defined as patients demonstrating both a long QTc and relatively low comorbidity index (CI) in the pre-HSCT setting) did not demonstrate excessive electrolyte abnormalities at the time of the ECG. However, frequent exposure to known QTcprolonging agents was noted. Overall NRM was not higher for this 'at-risk' group than for their counterparts who did not demonstrate a long QTc pre HSCT; however, trends toward increasing NRM were seen for the 'at-risk' group when presence of post-HSCT long QTc was considered in the analysis.
Not surprisingly, QTc characteristics for the cohort varied by age and gender in both the pre-HSCT settings (male gender shorter, nadir at 32 years), an observation well documented in the general population. 24 Interestingly, multivariable analysis showed that longer pre-HSCT QTc correlated with two underlying primary diseases: AML and MPD. For the former, a longer QTc tendency could result from previous anti-leukemic therapy, as anthracyclines have been described to prolong the QTc. [26] [27] [28] [29] However, QTc Reference group represents an expected change in QTc for a 40-year-old male with lymphoma undergoing autologous transplant. GvHD prophylaxis estimates were fit in a separate model that included age, gender and diagnosis but not graft type (because of dependence of GvHD prophylaxis on allograft versus autograft source). Abbreviations: CI = confidence interval; CSA = cyclosporine A; HSCT = hematopoietic stem cell transplantation; MA = myeloablative or maximal intensity conditioning; MMF = mycophenolate mofetil; RIC = reducedintensity conditioning; RG = reference group; QTc = corrected QT interval. a R 2 = 0.06; data for primary diagnoses with nonsignificant QTc associations not shown.
b Reference group represents an expected post-HSCT QTc for a 40-year-old male with lymphoma undergoing autologous transplant. GvHD prophylaxis estimates were fit in a separate model that included age, gender and diagnosis but not graft type (because of dependence of GvHD prophylaxis on allograft versus autograft source). was not similarly prolonged for other primary diagnostic groups, such as lymphoma or other malignancy, whose patients may also have increased likelihood of previous anthracycline exposure. In the MPD group, therapy with tyrosine kinase inhibitors may have contributed to QTc prolongation. 30, 31 For both groups, pre-HSCT maintenance on azole antifungal prophylaxis (such as fluconazole or voriconazole) and fluoroquinolone antibacterial prophylaxis (such as levofloxacin) may have also contributed to QTc prolongation. 32, 33 In contrast, patients presenting for HSCT as therapy for metabolic disorders demonstrated shorter QTc compared with others in the cohort. In general, these patients may have had less medication exposure before transplant compared with other populations seeking HSCT in our cohort. Although Hurler syndrome, comprising a significant portion of this group, has well-known myocardial, cardiac valvular and coronary arterial abnormalities, long QTc has not been described. 34 It is noteworthy that intended transplantation strategy did not correlate with pre-HSCT QTc, as use of reduced-intensity conditioning regimens is likely over-represented in patients with existing pre-HSCT medical comorbidities.
In this retrospective analysis, fewer patients in our cohort had evaluable post-HSCT QTc data, as screening ECG is not routinely performed following transplant. Indications for ECG acquisition were not discernible in our analysis, though typically are for clinical indications (for example, chest pain and/or rate/rhythm abnormalities detected on exam or monitoring). Post-HSCT QTc continued to correlate in multivariable analysis with age and gender (male gender, shorter; nadir at age 30 years). Interestingly, a trend toward longer QTc was noted in patients who received cyclosporine and mycophenolate mofetil for GvHD prophylaxis. Neither cyclosporine A nor mycophenolate mofetil has been described to prolong the QTc in the medical literature. It is noteworthy that transplant type did not correlate with observed post-HSCT QTc in this cohort. Although one might expect allogeneic graft and myeloablative conditioning to be associated with increased toxicity and supportive medication exposure, this did not translate to evidence of QTc prolongation. Although timing of pre-HSCT ECG acquisition was relatively homogeneous for the cohort, significant variability for post-HSCT ECG acquisition was noted, a clear limitation of a nonprospective study. As a significant proportion of patients in our cohort did not undergo post-HSCT ECG, it is difficult to know if the findings in those who did can be generalized to the entire cohort. A particular consideration in this respect would be whether a difference in exposures to known QTc-prolonging medications (such as antifungal azoles, ondansetron and certain fluoroquinolones) would be expected between the two groups (those undergoing post-HSCT ECG and those not). Albeit not expected, this retrospective analysis cannot confirm this.
For patients who underwent multiple ECGs in each pre-and post-HSCT setting, we analyzed the mean QTc from all evaluable ECGs (per setting). An alternative approach was to consider each patient's maximum QTc (per setting) for analysis. However, we observed a strong, direct correlation between the maximum QTc observed and the frequency of observations per patient (data not shown), leading us to abandon the use of maximum QTc for analysis lest it obscure the clinical relevance of the data by statistical effect alone. Figure 2 . Incidence of NRM (death post HSCT due to any cause other than progression of the underlying disease that necessitated transplantation): (a) NRM stratified by pre-HSCT 'at-risk' status and (b) NRM stratified by interplay between pre-HSCT 'at-risk' status and posttransplant mean QTc ('at risk' is defined as demonstrating long pre-HSCT mean QTc (males ⩾ 460 ms, females ⩾ 470 ms) without known HSCT-CI ⩾ 3; long QTc post-HSCT defined as mean value ⩾ 460 ms for males, and ⩾ 470 ms for females). Note: for patients without post-HSCT ECG, 2-year NRM was 3% for 32 'at-risk' patients and 5% for 383 patients who were not 'at risk' .
The evaluable cohort demonstrated clear evidence of QTc prolongation between pre-and post-HSCT time points, with a modest median prolongation of 16 ms. In multivariable analysis, factors correlating with degree of QTc change were the diagnoses of MPD and AML. For both, less prolongation of the QTc was observed. As AML and MPD were noted to predict longer QTc in the pre-HSCT setting, these findings, combined with the observation that the primary diagnosis did not predict absolute post-HSCT QTc, perhaps suggest that the transplant process (including conditioning and supportive therapies) 'equalized' the cohort. However, relatively small numbers of patients in the MPD category make it difficult to draw definitive conclusions for this group of patients. Although for the entire cohort, it is possible that greater variability in the timing of the post-HSCT ECGs obscured our ability to detect post-HSCT QTc differences across diagnoses.
The primary objective of our analysis was to describe QTc characteristics and change in a large HSCT cohort. Yet, a wellknown link between QTc and risk for malignant arrhythmias and sudden cardiac events exists in the general population. 35 Ideally, a primary outcome of our analysis would have been the incidence of sudden cardiac events (including dysrhythmia) as predicted by QTc. However, this was precluded by the study's retrospective nature. Therefore, we assessed the association between pre-HSCT QTc and NRM. Since both the variable (QTc) and outcome (NRM) may be confounded by comorbidity, we defined an 'at-risk' subset based on pre-HSCT QTc after excluding patients with pre-HSCT-CI ⩾ 3. Although lessons from familial long QT syndromes suggest that true risk of cardiac event depends upon actual QTc (as opposed to risk stratification about an arbitrary cut off point), we used gender-specific widely published and accepted in the field to guide these criteria. 17, 36 Interestingly, this long QTc group did not demonstrate increased incidence in NRM post transplantation. However, for patients who underwent both pre-and post-HSCT ECGs, the interplay of 'at-risk' status and a long QTc after transplantation trended toward differences in observed NRM outcome. 'At-risk' patients with long QTc post HSCT showed higher NRM, particularly evident in the first several months immediately following transplant. Clearly, the retrospective nature of this study limits the ability to draw conclusions about the impact of the pre-HSCT QTc on post-HSCT NRM; and, in fact, patients with more post-HSCT complications were probably more likely to undergo an evaluative ECG. Importantly, one would expect that a long QTc, if causative of NRM, would mediate sudden death via expression of an acute dysrhythmia, an outcome not identifiable in this analysis. Interestingly, two prospective studies have shown QT dispersion as a pre-transplant predictor of cardiac complications in smaller HSCT cohorts, although neither of the studies identified the QTc alone as predictive. 37, 38 Another report observed a high frequency of prolonged QTc following autologous HSCT in adults for systemic light chain amyloidosis with cardiac involvement; interestingly, that analysis suggested a role for intense prospective telemetry monitoring in these highrisk cardiac patients who experienced frequent clinicallysignificant ventricular dysrhythmias. 39 We clearly demonstrate QTc interval prolongation in a large, diverse cohort of pediatric and adult patients undergoing HSCT at our center. A remaining clinical challenge for the transplant physician and cardiology consultant, alike, is the ideal management of those with long or borderline-long pre-HSCT QT. We recommend a reasonable approach, including a rational exclusion of familial LQTS in the appropriate historical setting, correction of electrolyte disturbances when present, cessation of offending drugs when feasible, and consideration of beta-blockade for those with persistently prolonged interval. However, prospective studies may better assess the link between the QTc interval and sudden cardiac events in HSCT, ultimately informing the clinician about ideal surveillance and intervention strategies.
